Michael E. Prime

Abingdon, ENG OX144RZ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Correction to "Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates".

Correction to "Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates".

Journal: Journal of medicinal chemistry

Published: September 26, 2025

Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates.

Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates.

Journal: Journal of medicinal chemistry

Published: July 07, 2025

Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.

Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.

Journal: Journal of medicinal chemistry

Published: December 22, 2022

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.

Journal: Science translational medicine

Published: February 02, 2022

[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.

[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.

Journal: Journal of medicinal chemistry

Published: August 05, 2021

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.

Journal: Scientific reports

Published: June 18, 2021

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.

Journal: Journal of medicinal chemistry

Published: July 15, 2020

Major trauma patients with spinal fractures have more complex injuries than non-major trauma patients.

Major trauma patients with spinal fractures have more complex injuries than non-major trauma patients.

Journal: The bone & joint journal

Published: January 29, 2015

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

Journal: Journal of medicinal chemistry

Published: January 16, 2015

Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).

Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).

Journal: Journal of biomolecular screening

Published: May 22, 2013

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: September 04, 2012

SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

Journal: ACS medicinal chemistry letters

Published: August 15, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026